Clinical trials: Relapsing Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis
Extension Study of MT-1303
To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT01890655
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 17 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 367 people
- Sponsor
- Tanabe Pharma Corporation
Fatigue in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
This study evaluated the effect of an individualized web-based physical training in fingolimod -treated patients.
- Trial name
- PACE (NCT01490840)
- Testing
- Physical exercise
- Where
- 32 sites in Germany
- Volunteers
- 178 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS
A phase IV, observational, survey-based study to measure compliance with Avonex® PS therapy in patients with Relapsing-Remitting Multiple Sclerosis, and to compare persistence on therapy 22 months after initial prescription of…
- Trial name
- COMPASS (NCT00675883)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Biogen
Multiple Sclerosis
[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis
This open-label positron emission tomography (PET) study is designed to determine the effect of ABT-555 on translocator protein expression level in participants with relapsing forms of multiple sclerosis.
- Trial name
- NCT02606630
- Testing
- ABT-555
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- AbbVie
Multiple Sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and…
- Trial name
- NCT00819195
- Testing
- Glatiramer acetate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis, Relapsing-Remitting
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing remitting multiple sclerosis, analyze the…
- Trial name
- NCT04625153
- Testing
- RC18 160mg, RC18 240mg
- Where
- China
- Volunteers
- 8 people
- Sponsor
- RemeGen Co., Ltd.
Multiple Sclerosis (MS) - Relapsing-remitting
Effects of Sailing and Cooing in the Quality of Life of Multiple Sclerosis Individuals
In this study, we aim to evaluate the impact of head and neck cooling on symptoms and psychological states in individuals with Multiple Sclerosis (MS) during a 7-day Oceans of Hope Challenge sailing trip around the Greek islands…
- Trial name
- MS Sailing (NCT06915272)
- Testing
- Head and Neck Cooling Intervention
- Where
- Greece
- Volunteers
- 45 people
- Sponsor
- University of Thessaly
Multiple Sclerosis
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
This national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS.
- Trial name
- PRO-MSACTIVE (NCT03589105)
- Testing
- Ocrelizumab 300 mg, Ocrelizumab 600 mg
- Where
- 46 sites in France
- Volunteers
- 423 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
This research study is being conducted in the U.S. and Europe to evaluate the safety and efficacy of daclizumab for the treatment of multiple sclerosis (MS).
- Trial name
- NCT00109161
- Testing
- Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
- Where
- 36 sites in United States, Canada
- Volunteers
- 270 people
- Sponsor
- PDL BioPharma, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT.
- Trial name
- NCT02637856
- Testing
- Ocrelizumab
- Where
- 82 sites in United States, Canada
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
The aim of this study is to identify whether it is possible to safely discontinue treatment in relapsing-onset MS patients who have shown no evidence of active inflammation in the years prior to inclusion clinically and/or…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- DOT-MS (NCT04260711)
- Testing
- DMT
- Where
- Netherlands
- Volunteers
- 130 people
- Sponsor
- Amsterdam UMC, location VUmc
Relapsing Remitting Multiple Sclerosis
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod
This is an observational study to develop new hypothesis regarding the dynamic and safety of switching from natalizumab to fingolimod: Comparison of disease activity (clinical and MRI) during the year after change of therapy in…
- Trial name
- NCT02277964
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Basel, Switzerland
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Relapsing-remitting Multiple Sclerosis
Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis
Multiple sclerosis (MS) is the most common inflammatory demyelinating chronic disease of the central nervous system and the second leading cause of disability in young adults. Motor deficits also involve respiratory muscles.
- Trial name
- NCT02104492
- Testing
- a 12-week Respiratory Muscles Training Program (RMTP), Active Comparator
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- University of Malaga
Nutrition Habits in Multiple Sclerosis
Relationship Between the Nutritional Habits and Relapsing and Disability Rates in Patient With Multiple Sclerosis.
patient with multiple sclerosis will undergo and completed comprehensive survey measuring body mass index and assessment of obesity ,health related quality of life,disability,relapsing and complete data on their dietary habits.
- Trial name
- NCT04110171
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Sclerosis
Influence of Therapeutic Failure on the Psychosocial Experience in Multiple Sclerosis
Multiple sclerosis (MS), an inflammatory, neurodegenerative disease of the central nervous system, affects around 120,000 patients in France and is the leading cause of non-traumatic disability in young adults.
- Trial name
- INPSYSEP (NCT07372599)
- Testing
- Questionnaires
- Volunteers
- 150 people
- Sponsor
- University Hospital, Caen
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04448977
- Testing
- Ocrevus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis
The prevalence of sexual dysfunction is higher among women with multiple sclerosis (MS) than women in the general population. The presence of sexual dysfunction is associated with decreased well-being and quality of life.
- Trial name
- BIPAMS-SD (NCT04768777)
- Testing
- Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis…
- Trial name
- EXTEND (NCT01797965)
- Testing
- BIIB019 (Daclizumab)
- Where
- 222 sites in United States, Argentina and 25 more
- Volunteers
- 1,501 people
- Sponsor
- Biogen
Multiple Sclerosis
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.
- Trial name
- PROOF (NCT00599274)
- Testing
- Interferon beta-1a
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 136 people
- Sponsor
- Biogen